Lipocalin-type prostaglandin D Synthase is associated with coronary vasospasm and vasomotor reactivity in response to acetylcholine

Circulation Journal

Volumn 75, Issue 4, 2011, Pages 897-904

  Matsumoto, Tetsuya ^a   Eguchi, Yutaka ^a   Oda, Hiroshi ^b   Yamane, Tetsunobu ^a   Tarutani, Yasuhiro ^c   Ozawa, Tomoya ^a   Hayashi, Hideki ^a   Nakae, Ichiro ^a   Horie, Minoru ^a   Urade, Yoshihiro ^d  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Maruha Nichiro Holdings Inc   (Japan)

^c Okamura Memorial Hospital   (Japan)

^d OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

Acetylcholine; Coronary spasm; Lipocalin type prostaglandin D synthase

Indexed keywords

ACETYLCHOLINE; LIPOCALIN TYPE PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D SYNTHASE; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY SPASM; DISEASE ASSOCIATION; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PROVOCATION TEST; SCREENING TEST; THORAX PAIN; VASOMOTOR REFLEX;

ACETYLCHOLINE; ANGINA PECTORIS; CORONARY ANGIOGRAPHY; CORONARY VASOSPASM; CORONARY VESSELS; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MALE; MIDDLE AGED; PROSTAGLANDIN D2; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 79953655094     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0902     Document Type: Article

References (33)

1. Hayaishi O, Urade Y. Prostaglandin D2 in sleep-wake regulation: Recent progress and perspectives. Neuroscientist 2002; 8: 12-15.
2. Eguchi N, Minami T, Shirafuji N, Kanaoka Y, Tanaka T, Nagata A, et al. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA 1999; 96: 726-730.
3. Bushfield M, McNicol A, MacIntyre DE. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2: Differential sensitivity of platelet transduction processes and functional response to inhibition by cyclic AMP. Biochem J 1985; 232: 267-271.
4. Braun M, Schror K. Prostaglandin D2 relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation. Circ Res 1992; 71: 1305-1313.
5. Urade Y, Fujimoto N, Hayaishi O. Purification and characterization of rat brain prostaglandin D synthase. J Biol Chem 1985; 260: 12410-12415.
6. Hoffman A, Conradt HS, Gross G, Nimtz M, Lottspeich F, Wurster U. Purification and chemical characterization of β-trace protein from human cerebrospinal fluid: Its identification as prostaglandin D synthase. J Neurochem 1993; 61: 451-456.
7. Watanabe K, Urade Y, Mäder M, Murphy C, Hayaishi O. Identification of beta-trace as prostaglandin D synthase. Biochem Biophys Res Commun 1994; 203: 1110-1116.
8. Eguchi Y, Eguchi N, Oda H, Seiki K, Kijima Y, Matsu-ura Y, et al. Expression of lipocalin-type prostaglandin D synthase (β-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 1997; 94: 14689-14894.
9. Oda H, Eguchi N, Urade Y, Hayaishi O. Quantitative sandwich enzyme-linked immunosorbent assay for human secretory prosta glandin D synthase (β-trace). Proc Japan Acad 1996; 72: 108-111.
10. Hirawa N, Uehara Y, Yamakado M, Toya Y, Gomi T, Ikeda T, et al. Lipocalin-type prostaglandin D synthase in essential hypertension. Hypertension 2002; 39: 449-454.
11. Inoue T, Eguchi Y, Matsumoto T, Kijima Y, Kato Y, Ozaki Y, et al. Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. Atherosclerosis 2008; 201: 385-391.
12. Miwa Y, Oda H, Shiina Y, Shikata K, Tsushima M, Nakano S, et al. Association of serum lipocalin-type prostaglandin D synthase levels with subclinical atherosclerosis in untreated asymptomatic subjects. Hypertens Res 2008; 31: 1931-1939.
13. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: Lessons from animal models. Jpn Circ J 2000; 64: 1-12.
14. Miwa K, Fujita M, Sasayama S. Recent insights into the mechanisms, predisposing factors, and racial differences of coronary vasospasm. Heart Vessels 2005; 20: 1-7.
15. Yasue H, Nakagawa H, Itoh T, Harada E, Mizuno Y. Coronary artery spasm: Clinical features, diagnosis, pathogenesis, and treatment. J Cardiol 2008; 51: 2-17.
16. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): Digest version. Circ J 2010; 74: 1745-1762.
17. Taba Y, Sasaguri T, Miyagi M, Abumiya T, Miwa Y, Ikeda T, et al. Fluid shear stress induces lipocalin-type prostaglandin D2 synthase expression in vascular endothelial cells. Circ Res 2000; 86: 967-973.
18. Ando J, Yamamoto K. Vascular mechanobiology: Endothelial cell responses to fluid shear stress. Circ J 2009; 73: 1983-1992.
19. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41: 1373-1379.
20. Oda H, Shiina Y, Seiki K, Sato N, Eguchi N, Urade Y. Development and evaluation of a practical ELISA for human urinary lipocalintype prostaglandin D synthase. Clin Chem 2002; 48: 1445-1453.
21. Itoh T, Mizuno Y, Harada E, Yoshimura M, Ogawa H, Yasue H. Coronary spasm is associated with chronic low-grade inflammation. Circ J 2007; 71: 1074-1078.
22. Han F, Takeda K, Ishikawa K, Ono M, Date F, Yokoyama S, et al. Induction of lipocalin-type prostaglandin D synthase in mouse heart under hypoxemia. Biochem Biophys Res Commun 2009; 385: 449-453.
23. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 2009; 196: 193-222.
24. Masuda T, Yasue H, Ogawa H, Misumi I, Sakamoto T, Okubo H, et al. Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J 1992; 124: 314-319.
25. Ogawa H, Yasue H, Oshima S, Okumura K, Matsuyama K, Obata K. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 1989; 80: 1617-1626.
26. Negoro H, Soo Shin W, Hakamada-Taguchi R, Eguchi N, Urade Y, Goto A, et al. Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens 2002; 20: 1347-1354.
27. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-812.
28. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest 2003; 112: 945-955.
29. Takano H, Komuro I. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ J 2009; 73: 214-220.
30. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ 2nd, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985; 313:1138-1141.
31. Laine P, Kaartinen M, Penttila A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 1999; 99: 361-369.
32. Sueda S, Kohno H, Inoue K, Fukuda H, Suzuki J, Watanabe K, et al. Intracoronary administration of a thromboxane A2 synthase inhibitor relieves acetylcholine-induced coronary spasm. Circ J 2002; 66: 826-830.
33. Takagi S, Goto Y, Hirose E, Terashima M, Sakuragi S, Suzuki S, et al. Successful treatment of refractory vasospastic angina with corticosteroids: Coronary arterial hyperactivity caused by local inflammation? Circ J 2004; 68: 17-22.